[go: up one dir, main page]

MX2014001218A - Tratamiento de cancer de mama. - Google Patents

Tratamiento de cancer de mama.

Info

Publication number
MX2014001218A
MX2014001218A MX2014001218A MX2014001218A MX2014001218A MX 2014001218 A MX2014001218 A MX 2014001218A MX 2014001218 A MX2014001218 A MX 2014001218A MX 2014001218 A MX2014001218 A MX 2014001218A MX 2014001218 A MX2014001218 A MX 2014001218A
Authority
MX
Mexico
Prior art keywords
breast cancer
cancer treatment
compounds
triple negative
cancer cells
Prior art date
Application number
MX2014001218A
Other languages
English (en)
Other versions
MX359664B (es
Inventor
Andrew A Protter
Jennifer Richer
Dawn Cochrane
Original Assignee
Medivation Prostate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48192564&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2014001218(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medivation Prostate Therapeutics Inc filed Critical Medivation Prostate Therapeutics Inc
Publication of MX2014001218A publication Critical patent/MX2014001218A/es
Publication of MX359664B publication Critical patent/MX359664B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente describe el uso de uno o más compuestos que caen dentro del alcance de una o más fórmulas estructurales I, II, II, IV, V, o VI para tratar cáncer de mama negativo triple. Los compuestos útiles par tratar cáncer de mama incluyen aquellos compuestos de las fórmulas I, II, II, IV, V, o VI que inhiben la proliferación de células de cáncer de mama y/o conducen a la muerte de células de cáncer de mama, especialmente cáncer de mama negativo triple.
MX2014001218A 2011-07-29 2012-07-27 Tratamiento de cáncer de mama. MX359664B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161513361P 2011-07-29 2011-07-29
PCT/US2012/048471 WO2013066440A1 (en) 2011-07-29 2012-07-27 Treatment of breast cancer

Publications (2)

Publication Number Publication Date
MX2014001218A true MX2014001218A (es) 2014-08-22
MX359664B MX359664B (es) 2018-10-05

Family

ID=48192564

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014001218A MX359664B (es) 2011-07-29 2012-07-27 Tratamiento de cáncer de mama.

Country Status (18)

Country Link
US (4) US9517229B2 (es)
EP (4) EP2739153B1 (es)
JP (2) JP6158180B2 (es)
KR (1) KR101923250B1 (es)
CN (1) CN103997894B (es)
BR (1) BR112014002200A2 (es)
CA (1) CA2843417C (es)
CY (1) CY1121038T1 (es)
DK (1) DK2739153T3 (es)
EA (1) EA028452B1 (es)
ES (1) ES2696074T3 (es)
HU (1) HUE040524T2 (es)
MX (1) MX359664B (es)
PH (1) PH12014500248B1 (es)
PL (1) PL2739153T3 (es)
PT (1) PT2739153T (es)
SI (1) SI2739153T1 (es)
WO (1) WO2013066440A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6158180B2 (ja) * 2011-07-29 2017-07-05 メディベイション プロステイト セラピューティクス， インコーポレイテッド 乳がんの処置
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
IL312316A (en) 2012-09-26 2024-06-01 Aragon Pharmaceuticals Inc Antiandrogens for the treatment of castration-resistant prostate cancer without metastases
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
SG11201508302PA (en) 2013-04-17 2015-11-27 Signal Pharm Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
JP6945587B2 (ja) * 2013-11-07 2021-10-06 デシフェラ ファーマシューティカルズ，エルエルシー ガンの処置に有用なｔｉｅ２キナーゼの阻害方法
CN105873440B (zh) * 2013-11-07 2018-06-01 德西费拉制药有限责任公司 抑制tie2激酶的组合物在制备治疗癌症的药物中的用途
US10238630B2 (en) 2014-05-28 2019-03-26 Eisai R&D Management Co., Ltd. Use of eribulin and poly (ADP ribose) polymerase (PARP) inhibitors as combination therapy for the treatment of cancer
RU2017120330A (ru) * 2014-12-12 2019-01-14 Медивэйшн Простейт Терапьютикс, Ллс Способ прогнозирования ответа на терапевтические агенты для лечения рака молочной железы и способ лечения рака молочной железы
EP3265063A4 (en) 2015-03-03 2018-11-07 Cureport, Inc. Dual loaded liposomal pharmaceutical formulations
EP3265059A4 (en) 2015-03-03 2018-08-29 Cureport Inc. Combination liposomal pharmaceutical formulations
CN104857517B (zh) * 2015-05-14 2018-04-27 南京海纳医药科技股份有限公司 一种恩杂鲁胺软胶囊及其制备方法
US9963433B2 (en) * 2016-01-29 2018-05-08 Wayne State University Anticancer drugs including the chemical structures of an androgen receptor ligand and a histone deacetylase inhibitor
SG11201912403SA (en) 2017-06-22 2020-01-30 Celgene Corp Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
CA3079135A1 (en) 2017-10-16 2019-04-25 Arturo Molina Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
CN107987055A (zh) * 2017-12-19 2018-05-04 刘秀云 硫代咪唑二酮类雄激素受体拮抗剂及其用途
CN118416236A (zh) 2018-01-31 2024-08-02 德西费拉制药有限责任公司 治疗胃肠道间质瘤的组合疗法
BR112020015572A2 (pt) 2018-01-31 2021-02-02 Deciphera Pharmaceuticals, Llc terapia de combinação para o tratamento da mastocitose
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CA3121199A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
WO2020185812A1 (en) 2019-03-11 2020-09-17 Teva Pharmaceuticals International Gmbh Solid state forms of ripretinib
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
JP2022544234A (ja) 2019-08-12 2022-10-17 デシフェラ・ファーマシューティカルズ，エルエルシー 胃腸間質腫瘍を治療するためのリプレチニブ
SMT202400484T1 (it) 2019-12-30 2025-01-14 Deciphera Pharmaceuticals Llc Composizioni di 1-(4-bromo-5-(1-etil-7-(metilammino)-2-osso-1,2-diidro-1,6-naftiridin-3-il)-2-fluorofenil)-3-fenilurea
CA3163053A1 (en) 2019-12-30 2021-07-08 Michael D. Kaufman Amorphous kinase inhibitor formulations and methods of use thereof
JP2023536636A (ja) * 2020-08-03 2023-08-28 オンコサイト・コーポレイション 腫瘍の分類及び応答性の予測
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
KR20240148945A (ko) 2005-05-13 2024-10-11 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴히단토인 화합물
WO2007061876A2 (en) 2005-11-23 2007-05-31 University Of Utah Research Foundation Methods and compositions involving intrinsic genes
CN101454002B (zh) 2006-03-27 2011-06-08 加利福尼亚大学董事会 用于治疗前列腺癌和与雄激素受体相关的疾病的雄激素受体调节剂
KR20160027254A (ko) 2006-03-29 2016-03-09 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴티오히단토인 화합물
JP5535925B2 (ja) 2007-10-26 2014-07-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア アンドロゲン受容体調節物質としてのジアリールヒダントイン化合物
US8450290B2 (en) 2007-11-26 2013-05-28 Enzon Pharmaceuticals, Inc. Methods for treating androgen receptor dependent disorders including cancers
WO2009114534A1 (en) 2008-03-14 2009-09-17 The Regents Of The University Of California Multi-gene classifiers and prognostic indicators for cancers
DK2297359T3 (en) 2008-05-30 2014-02-24 Univ Utah Res Found Gene expression profiles to predict the outcome of breast cancer
CN102421291A (zh) 2009-02-24 2012-04-18 梅迪维新前列腺医疗股份有限公司 具体的二芳基乙内酰脲和二芳基乙内酰硫脲化合物
EP2416657A4 (en) * 2009-04-09 2012-09-05 Medivation Prostate Therapeutics Inc COMPOUNDS COMPRISING SUBSTITUTED DI-ARYLHYDANTOIDS AND DI-ARYLTHIOHYDANTOINES AND METHODS OF USE THEREOF
US8507195B2 (en) * 2009-08-20 2013-08-13 The Regents Of The University Of Colorado MiRNAs dysregulated in triple-negative breast cancer
WO2011044327A1 (en) 2009-10-07 2011-04-14 Medivation Prostate Therapeutics, Inc. Substituted phenylcarbamoyl alkylamino arene compounds and n,n'-bis-arylurea compounds
US9066963B2 (en) 2011-03-15 2015-06-30 The University Of North Carolina At Chapel Hill Methods of treating breast cancer with anthracycline therapy
JP6158180B2 (ja) * 2011-07-29 2017-07-05 メディベイション プロステイト セラピューティクス， インコーポレイテッド 乳がんの処置
CA2857505A1 (en) 2011-11-30 2013-06-06 The University Of North Carolina At Chapel Hill Methods of treating breast cancer with taxane therapy
CA2882621A1 (en) 2012-08-23 2014-02-27 The Regents Of The University Of Colorado, A Body Corporate Method for determining breast cancer treatment
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
US20140154681A1 (en) 2012-11-12 2014-06-05 Nanostring Technologies, Inc. Methods to Predict Breast Cancer Outcome
US10679730B2 (en) 2013-05-28 2020-06-09 The University Of Chicago Prognostic and predictive breast cancer signature
RU2017120330A (ru) 2014-12-12 2019-01-14 Медивэйшн Простейт Терапьютикс, Ллс Способ прогнозирования ответа на терапевтические агенты для лечения рака молочной железы и способ лечения рака молочной железы

Also Published As

Publication number Publication date
JP2014524934A (ja) 2014-09-25
PH12014500248A1 (en) 2014-03-17
EP3791724A1 (en) 2021-03-17
HK1198867A1 (en) 2015-06-19
MX359664B (es) 2018-10-05
ES2696074T3 (es) 2019-01-14
CN103997894A (zh) 2014-08-20
EP3610731A1 (en) 2020-02-19
WO2013066440A9 (en) 2013-07-18
EA028452B1 (ru) 2017-11-30
EA201400178A1 (ru) 2014-11-28
US20170087132A1 (en) 2017-03-30
US9517229B2 (en) 2016-12-13
SI2739153T1 (sl) 2018-12-31
EP2739153A1 (en) 2014-06-11
CN103997894B (zh) 2016-08-24
PH12014500248B1 (en) 2018-08-31
KR20140107174A (ko) 2014-09-04
US20140296312A1 (en) 2014-10-02
HK1201413A1 (en) 2015-09-04
CY1121038T1 (el) 2019-12-11
KR101923250B1 (ko) 2018-11-28
CA2843417A1 (en) 2013-05-10
JP6158180B2 (ja) 2017-07-05
PL2739153T3 (pl) 2019-04-30
US10111861B2 (en) 2018-10-30
US20210069154A1 (en) 2021-03-11
BR112014002200A2 (pt) 2017-03-07
HUE040524T2 (hu) 2019-03-28
DK2739153T3 (en) 2018-12-03
EP2739153B1 (en) 2018-08-22
US20190262315A1 (en) 2019-08-29
CA2843417C (en) 2018-08-21
WO2013066440A1 (en) 2013-05-10
EP3430907A1 (en) 2019-01-23
JP2017141269A (ja) 2017-08-17
EP2739153A4 (en) 2015-03-11
PT2739153T (pt) 2018-11-28

Similar Documents

Publication Publication Date Title
MX2014001218A (es) Tratamiento de cancer de mama.
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
CL2020000215A1 (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad nlrp.
CO2019011543A2 (es) Inhibidores de pd-1/pd-l1
NI201900019A (es) Inhibidores de procesos metabólicos celulares
UY37124A (es) Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
MX377384B (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cáncer.
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
UY34201A (es) Compuestos de azaindol y métodos para el tratamiento de vih.
UY33883A (es) Novedosos derivados heterocíclicos
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
CR20160022A (es) Compuestos de n,6-bis (aril o heteroaril) 1,3,5- triazin-2,4-diamina como inhibidores de idh2 mutantes para el tratamiento del cancer
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
UY35590A (es) Nuevos compuestos para el tratamiento del cáncer
CU20140048A7 (es) Novedosos derivados de purina útiles en el tratamiento del cáncer y trastornos neurodegenerativos
CL2015001246A1 (es) Derivados de bendamustina y los metodos de su uso
CL2016001151A1 (es) Derivados de purina 2,6-sustituidos y su uso en el tratamiento de trastorno proliferativos.
MX370900B (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 cinasas.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MX2017004600A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
ECSP17010238A (es) Compuestos novedosos de pirimidina sustituidos
CO2017001506A2 (es) Compuestos novedosos de pirimidina sustituidos
MX377528B (es) Compuestos de platino funcionalizados con monomaleimida para la terapia del cáncer.
DOP2015000298A (es) Compuestos nuevos para el tratamiento del cáncer

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: ARESCO TECHNOLOGIES, LLC

FG Grant or registration